Clinical Trial Update: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two rivaroxaban strategies versus oral vitamin K antagonist in patients with atrial fibrillation undergoing percutaneous coronary inter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Percutaneous Coronary Intervention

Drugs mentioned

• Oral vitamin K antagonist (vitamin K antagonist)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: Atrial Fibrillation, Percutaneous Coronary Intervention | Phase 3 | Status: COMPLETED | Results posted: 2017-07-31